Quick orientationEvidence update: 6 October 2026
What is LL-37?
LL-37 is one of the body's own host-defence peptides. It is part of the cathelicidin system and can interact with microbes, immune signalling and wound-healing biology.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Laboratory research plus topical wound studies; excessive or misplaced LL-37 activity is also implicated in inflammatory disease.
What the mechanism suggests
Human cathelicidin host-defence peptide with antimicrobial and immune-modulating activity.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Human cathelicidin host-defence peptide with antimicrobial and immune-modulating activity.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
HEAL LL-37 Phase IIb venous-ulcer trial — 2021
Double-blind placebo-controlled Phase IIb · 148 patientsTopical LL-37 at 0.5 or 1.6 mg/mL did not significantly improve healing across the full study population. A post-hoc subgroup with larger wounds showed signals that need prospective confirmation.
An encouraging first-in-human signal did not translate into a positive whole-cohort Phase IIb result.
What it doesn't prove: Topical wound treatment only; subgroup result was post hoc.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| First-in-human VLU trial | 0.5, 1.6 or 3.2 mg/mL topical; applied twice weekly | 4 weeks | Fixed parallel concentrations | 34-person randomized trial |
| Later multicentre VLU trial | 0.5 or 1.6 mg/mL; 25 µL/cm² wound = 12.5 or 40 µg/cm² | 13 weeks, twice weekly | Fixed | Randomized multicentre human trial |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Injectable community pattern | ~100–200 mcg SC once or twice daily | Often 2–4 weeks | Usually fixed | Community only |
| Higher community pattern | ~250–500 mcg/day SC | Short courses | No validated titration | Community; inconsistent |
Human evidence is TOPICAL wound treatment. It does not establish a systemic injectable dose; PP should show concentration, volume per wound area and active µg/cm² separately.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Biologically active does not mean universally beneficial; route and context matter greatly.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
An encouraging first-in-human signal did not translate into a positive whole-cohort Phase IIb result.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.